JP2021501587A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501587A5 JP2021501587A5 JP2020524366A JP2020524366A JP2021501587A5 JP 2021501587 A5 JP2021501587 A5 JP 2021501587A5 JP 2020524366 A JP2020524366 A JP 2020524366A JP 2020524366 A JP2020524366 A JP 2020524366A JP 2021501587 A5 JP2021501587 A5 JP 2021501587A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- domain
- seq
- construct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 88
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 76
- 210000004027 cell Anatomy 0.000 claims description 68
- 102000025171 antigen binding proteins Human genes 0.000 claims description 31
- 108091000831 antigen binding proteins Proteins 0.000 claims description 31
- 108020004707 nucleic acids Proteins 0.000 claims description 30
- 102000039446 nucleic acids Human genes 0.000 claims description 30
- 150000007523 nucleic acids Chemical class 0.000 claims description 30
- 230000003834 intracellular effect Effects 0.000 claims description 29
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 24
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 24
- 239000013604 expression vector Substances 0.000 claims description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 8
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 8
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 3
- 208000017604 Hodgkin disease Diseases 0.000 claims description 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 3
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 3
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 3
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 241000713666 Lentivirus Species 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 230000002489 hematologic effect Effects 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 206010061692 Benign muscle neoplasm Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 201000004458 Myoma Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 108010083359 Antigen Receptors Proteins 0.000 claims 1
- 102000006306 Antigen Receptors Human genes 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000004700 fetal blood Anatomy 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 210000002826 placenta Anatomy 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762581466P | 2017-11-03 | 2017-11-03 | |
| US62/581,466 | 2017-11-03 | ||
| PCT/IB2018/058642 WO2019087151A1 (en) | 2017-11-03 | 2018-11-02 | Cd38-directed chimeric antigen receptor constructs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021501587A JP2021501587A (ja) | 2021-01-21 |
| JP2021501587A5 true JP2021501587A5 (https=) | 2021-12-09 |
Family
ID=64277751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020524366A Pending JP2021501587A (ja) | 2017-11-03 | 2018-11-02 | Ｃｄ３８指向性キメラ抗原受容体構築物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11760806B2 (https=) |
| EP (1) | EP3704156A1 (https=) |
| JP (1) | JP2021501587A (https=) |
| KR (1) | KR20200076732A (https=) |
| CN (1) | CN111542545A (https=) |
| AU (1) | AU2018362014A1 (https=) |
| CA (1) | CA3080109A1 (https=) |
| WO (1) | WO2019087151A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202008568WA (en) | 2018-03-09 | 2020-10-29 | Sorrento Therapeutics Inc | Dimeric antigen receptors (dar) |
| CN112313250B (zh) * | 2018-06-20 | 2024-10-01 | 索伦托药业有限公司 | 结合cd38的变体抗体 |
| US20200345725A1 (en) | 2019-01-11 | 2020-11-05 | Omeros Corporation | Methods and Compositions for Treating Cancer |
| CA3144961A1 (en) * | 2019-07-01 | 2021-01-07 | Sorrento Therapeutics, Inc. | Heterodimeric antibodies that bind to cd38 and cd3 |
| CN114258401B (zh) * | 2019-07-16 | 2025-08-12 | Inserm(法国国家健康医学研究院) | 对cd38具有特异性的抗体及其用途 |
| US20220273716A1 (en) * | 2019-07-25 | 2022-09-01 | Celularity Inc. | Populations of natural killer cells comprising a cd38 chimeric antigen receptor |
| WO2022081486A1 (en) * | 2020-10-12 | 2022-04-21 | Sorrento Therapeutics, Inc. | Cd19-directed chimeric antigen receptor constructs |
| CN113663061A (zh) * | 2021-08-04 | 2021-11-19 | 上海优卡迪生物医药科技有限公司 | Cd38在制备car-t药物中的应用 |
| CN113893338A (zh) * | 2021-11-04 | 2022-01-07 | 苏州大学附属第一医院 | Cd38 car-t细胞在慢性粒细胞白血病急髓变中的应用 |
| EP4612188A2 (en) * | 2022-11-02 | 2025-09-10 | Medisix Therapeutics, Inc. | Methods and systems for production of engineered t-cells |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| DE69334095T2 (de) * | 1992-07-17 | 2007-04-12 | Dana-Farber Cancer Institute, Boston | Verfahren zur intrazellulären Bindung von zielgerichteten Molekülen |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| EP2567976B1 (en) | 2005-03-23 | 2017-07-19 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| EP2860192B1 (en) | 2005-10-12 | 2017-09-27 | MorphoSys AG | Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38 |
| DK2496698T3 (en) | 2009-11-03 | 2019-04-15 | Hope City | TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION |
| DK2580243T3 (da) | 2010-06-09 | 2020-01-13 | Genmab As | Antibodies against human cd38 |
| ES2754394T3 (es) | 2010-09-08 | 2020-04-17 | Chemotherapeutisches Forschungsinstitut Georg Speyer Haus | Receptores de antígenos quiméricos con una región bisagra optimizada |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| AU2013327136A1 (en) | 2012-10-02 | 2015-04-16 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
| SG10201803288RA (en) | 2013-10-31 | 2018-05-30 | Sanofi Sa | Specific anti-cd38 antibodies for treating human cancers |
| ES3063961T3 (en) * | 2014-02-14 | 2026-04-21 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| CN107531800B (zh) | 2014-07-25 | 2021-08-10 | 赛拉福柯蒂斯公司 | 用于嵌合抗原受体分子的调控表达的慢病毒载体 |
| TWI805109B (zh) | 2014-08-28 | 2023-06-11 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
| CN107002084B (zh) * | 2014-09-19 | 2021-09-10 | 希望之城公司 | 靶向IL13Rα2的共刺激嵌合抗原受体T细胞 |
| US20180021378A1 (en) * | 2014-12-31 | 2018-01-25 | Anthrogenesis Corporation | Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells |
| CN105802975B (zh) * | 2014-12-31 | 2020-04-14 | 浙江大学 | 靶向her2阳性肿瘤的细胞制备物及其用途 |
| ES2927119T3 (es) * | 2015-04-08 | 2022-11-02 | Sorrento Therapeutics Inc | Productos terapéuticos de anticuerpos que se unen a CD38 |
| CN108135937A (zh) * | 2015-04-15 | 2018-06-08 | 罗杰威廉姆斯医疗中心以普拉斯派克特查特凯尔Rwmc有限责任公司许可 | Car-t细胞的肝动脉灌注 |
| CA2994746A1 (en) * | 2015-08-11 | 2017-02-16 | Cellectis | Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation |
| GB201518817D0 (en) * | 2015-10-23 | 2015-12-09 | Autolus Ltd | Cell |
| WO2017070654A1 (en) * | 2015-10-23 | 2017-04-27 | Sorrento Therapeutics, Inc. | Programmable universal cell receptors and methods of using the same |
| JP2020508080A (ja) | 2017-02-21 | 2020-03-19 | ユーティレックス カンパニー リミテッド | Ｈｌａ−ｄｒ ｃａｒ−ｔ組成物ならびにその作製方法および使用方法 |
| SG11202008568WA (en) * | 2018-03-09 | 2020-10-29 | Sorrento Therapeutics Inc | Dimeric antigen receptors (dar) |
| CA3107378A1 (en) * | 2018-07-23 | 2020-01-30 | Magenta Therapeutics, Inc. | Use of an anti-cd2 antibody drug conjugate (adc) in allogeneic cell therapy |
| AU2019312200B2 (en) * | 2018-07-23 | 2024-11-14 | Heidelberg Pharma Research Gmbh | Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy |
-
2018
- 2018-11-02 CA CA3080109A patent/CA3080109A1/en active Pending
- 2018-11-02 KR KR1020207015716A patent/KR20200076732A/ko not_active Withdrawn
- 2018-11-02 JP JP2020524366A patent/JP2021501587A/ja active Pending
- 2018-11-02 EP EP18801058.1A patent/EP3704156A1/en not_active Withdrawn
- 2018-11-02 CN CN201880085146.7A patent/CN111542545A/zh active Pending
- 2018-11-02 AU AU2018362014A patent/AU2018362014A1/en not_active Abandoned
- 2018-11-02 WO PCT/IB2018/058642 patent/WO2019087151A1/en not_active Ceased
- 2018-11-02 US US16/179,850 patent/US11760806B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021501587A5 (https=) | ||
| US20260103502A1 (en) | Chimeric Antigen Receptor and Natural Killer Cells Expressing Same | |
| Wei et al. | Current landscape and future directions of bispecific antibodies in cancer immunotherapy | |
| JP2019525738A5 (https=) | ||
| Gross et al. | Therapeutic potential of T cell chimeric antigen receptors (CARs) in cancer treatment: counteracting off-tumor toxicities for safe CAR T cell therapy | |
| Zhao et al. | Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential | |
| JP2024099850A5 (https=) | ||
| JP2018506981A5 (https=) | ||
| HRP20241057T1 (hr) | Kimerni antigenski receptori na osnovu jedno-domenskih antitijela i načini njihove uporabe | |
| JP2025023921A (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| JP2019537433A5 (https=) | ||
| JP2019528769A5 (https=) | ||
| JP2019513370A5 (https=) | ||
| FI3710484T3 (fi) | CTLA-4:ää sitovia vasta-aineita ja niiden käyttöjä | |
| JP2018503380A5 (https=) | ||
| JP2020515239A5 (https=) | ||
| US20240342283A1 (en) | ROR1 CAR or ROR1 / CD19 Dual CAR T Cells for the Treatment of Tumors | |
| CN112028996A (zh) | 靶向bcma的单域抗体及其用途 | |
| JP2017537620A5 (https=) | ||
| JP2017513478A5 (https=) | ||
| CN105194661A (zh) | 时空可调性抑制病理性靶细胞的系统 | |
| JP2016508725A5 (https=) | ||
| Golay et al. | Design and validation of a novel generic platform for the production of tetravalent IgG1-like bispecific antibodies | |
| JP2016536322A5 (https=) | ||
| CN108034006A (zh) | 双抗原诱导的双功能互补作用 |